Delhi govt inspects 25 firms, collects 55 samples in crackdown on spurious anticancer drugs

New Delhi:  In a special enforcement drive against spurious and substandard anticancer drugs, Delhi government inspected 25 firms and collected 55 samples across the city, officials said on Monday.

Directed by the Health Minister Pankaj Kumar Singh, the drive was conducted by the Drugs Control Department to strengthen regulatory oversight of lifesaving cancer medicines and safeguard patients undergoing critical treatment, an official statement said.

The teams inspected retail and wholesale establishments dealing in anticancer drugs in areas around major hospital clusters and pharmaceutical markets in East, South, West and North-West Delhi.

Areas including Laxmi Nagar, Yusuf Sarai, Green Park, Okhla Industrial Area, Paschim Vihar, Dwarka and Rohini were inspected by the department, it added.

Six firms were found violating provisions of the Drugs and Cosmetics Rules, and legal action has been initiated against them, the statement said.

It said that a total of 33 legal samples and 22 specimen samples of anticancer drugs were collected for laboratory testing to verify their quality and compliance with prescribed standards. Further action will be taken based on the test results to prevent the circulation of any substandard or spurious medicines.

The minister emphasised that anticancer drugs are critical and lifesaving medicines and said that any compromise in quality poses serious risks to patient safety.

He said that surveillance of the supply chain has been intensified to ensure that only safe, effective and standards-compliant medicines reach hospitals, pharmacies and patients.

“These enforcement drives will continue relentlessly. As long as I am Health Minister, fake or substandard medicines will not be allowed to threaten the lives of Delhi’s citizens,” Singh added.

The government follows a zero-tolerance policy against fake medicines, particularly those used in cancer treatment, and that continuous inspections, strict enforcement and regular monitoring will remain a priority, the statement said.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’